Eir Ventures’ Investment in ISD Immunotech

Moalem Weitemeyer assisted Eir Ventures in the transaction.

SD Immunotech ApS (“ISD”), a biotech company developing new anti-inflammatory treatments, announced that Eir Ventures have completed an investment in the company. The financing will provide additional funding for development of the company’s lead candidate ISD017, a novel first in class therapy for treatment of Systemic Lupus Erythematosus (SLE).

iSD Immunotech is a biotech company that develops novel peptide therapeutics for the treatment of severe systemic lupus erythematosus (SLE), and the company has just been granted its first US patent by the US Patent and Trademark Office.

Eir Ventures is a Life science focused venture fund, with a strong foundation in the Nordic Biotech ecosystem, that will invest in companies at early stage, as well as more mature opportunities.

The Moalem Weitemeyer team included Mattias Vilhelm Warnøe Nielsen (Picture), Niels Christian Høgh Andersen and Nikolaj Lassen.

Involved fees earner: Niels Christian Høgh Andersen – Moalem Weitemeyer; Mattias Vilhelm Warnøe Nielsen – Moalem Weitemeyer;

Law Firms: Moalem Weitemeyer;

Clients: Eir Ventures;

Author: Federica Tiefenthaler